IQCN Variant 1: A Protein Involved in Fetal Development and Cancer

Target Name: IQCN

NCBI ID: G80726

IQCN

IQCN Variant 1: A Protein Involved in Fetal Development and Cancer

IQCN (IQCN variant 1) is a protein that is expressed in the human placenta and has been shown to play a role in the development and progression of various diseases, including cancer. Its unique structure and expression pattern have made it an attractive target for researchers to study and potentially develop into a drug.

IQCN variant 1 is a transmembrane protein that is expressed in the human placenta and has been shown to be involved in several important processes in fetal development and growth. One of the most significant functions of IQCN variant 1 is its role in the development and progression of cancer.

Studies have shown that IQCN variant 1 is involved in the regulation of cell proliferation and has been shown to play a role in the development of various types of cancer, including breast, ovarian, and prostate cancer. Additionally, IQCN variant 1 has also been shown to be involved in the regulation of cell apoptosis, which is the process by which cells die naturally.

IQCN variant 1 has also been shown to be involved in the regulation of cellular angiogenesis, which is the process by which new blood vessels form in the body. This is important for the development of blood vessels, which provide oxygen and nutrients to the developing fetus.

Another function of IQCN variant 1 is its role in the regulation of cellular signaling pathways. This is important for the development and progression of many diseases, including cancer.

IQCN variant 1 has also been shown to play a role in the regulation of the PI3K/Akt signaling pathway, which is an important pathway for the development and progression of many diseases, including cancer. Additionally, IQCN variant 1 has also been shown to play a role in the regulation of the TGF-β signaling pathway, which is also important for the development and progression of many diseases, including cancer.

IQCN variant 1 is also involved in the regulation of cellular adhesion, which is important for the development and progression of many diseases, including cancer. This is important for the development of tissues and organs and for the development of cancer.

In addition to its role in the regulation of cellular signaling pathways, IQCN variant 1 is also involved in the regulation of cellular signaling, which is important for the development and progression of many diseases, including cancer. This is important for the development of tissues and organs and for the development of cancer.

IQCN variant 1 is also involved in the regulation of cellular migration, which is important for the development and progression of many diseases, including cancer. This is important for the development of tissues and organs and for the development of cancer.

IQCN variant 1 is also involved in the regulation of cellular invasion, which is important for the development and progression of many diseases, including cancer. This is important for the development of tissues and organs and for the development of cancer.

In conclusion, IQCN variant 1 is a protein that is expressed in the human placenta and has been shown to play a role in the development and progression of various diseases, including cancer. Its unique structure and expression pattern make it an attractive target for researchers to study and potentially develop into a drug. Further research is needed to fully understand the role of IQCN variant 1 in fetal development and growth, as well as its potential as a drug target.

Protein Name: IQ Motif Containing N

Functions: Essential for spermiogenesis and fertilization (PubMed:36321563). May be required for manchette assembly in elongating spermatids (By similarity)

The "IQCN Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IQCN comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets